Evidence map›Paper›PMID 26704889›Full record

ArticleBioscience reports2015

Interrupted E2F1-miR-34c-SCF negative feedback loop by hyper-methylation promotes colorectal cancer cell proliferation.

Shu Yang, Bo Wu, Haimei Sun, Fengqing Ji, Tingyi Sun, Yan Zhao, Deshan Zhou

Open access · goldAbstract read
In one paragraph

Article in Bioscience reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Shu YangDepartment of Histology and Embryology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, P.R. China Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Beijing 100069, P.R. China Cancer Institute of Capital Medical University, Beijing 100069, P.R. China.
Bo WuDepartment of Histology and Embryology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, P.R. China Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Beijing 100069, P.R. China Cancer Institute of Capital Medical University, Beijing 100069, P.R. China.
Haimei SunDepartment of Histology and Embryology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, P.R. China Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Beijing 100069, P.R. China Cancer Institute of Capital Medical University, Beijing 100069, P.R. China.
Fengqing JiDepartment of Histology and Embryology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, P.R. China Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Beijing 100069, P.R. China Cancer Institute of Capital Medical University, Beijing 100069, P.R. China.
Tingyi SunDepartment of Histology and Embryology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, P.R. China Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Beijing 100069, P.R. China Cancer Institute of Capital Medical University, Beijing 100069, P.R. China.
Yan ZhaoClinical Research Centre for Autoimmune Liver Disease, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China.
Deshan ZhouDepartment of Histology and Embryology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, P.R. China Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Beijing 100069, P.R. China Cancer Institute of Capital Medical University, Beijing 100069, P.R. China zhoudeshan2008@163.com.
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumour suppressor miR-34c deficiency resulted from hyper-methylation in its promoter is believed to be one of the main causes of colorectal cancer (CRC). Till date, miR-34c has been validated as a direct target of p53; but previous evidence suggested other transcription factor(s) must be involved in miR-34c transcription. In the present study, we in the first place identified a core promoter region (-1118 to -883 bp) of pre-miR-34c which was embedded within a hyper-methylated CpG island. Secondly, E2F1 promoted miR-34c transcription by physical interaction with the miR-34c promoter at site -897 to -889 bp. The transcriptional activating effect of E2F1 on miR-34c was in a p53 independent manner but profoundly promoted in the presence of p53 with exposure to 5-aza-2'-deoxycytidine (DAC). Thirdly, stem cell factor (SCF), a miR-34c target, was specifically reduced upon an introduction of E2F1 which lead to suppression of CRC cell proliferation. The E2F1-suppressed cell proliferation was partially abrogated by additional miR-34c inhibitor, indicating that the anti-proliferation effect of E2F1 was probably through activating miR-34c-SCF axis. Finally, SCF/KIT signalling increased E2F1 production by reducing its proteosomal degradation dependent on PI3K/Akt-GSK3β pathway. In conclusion, our results suggested the existence of E2F1-miR-34c-SCF negative feedback loop which was interrupted by the hyper-methylation of miR-34c promoter in CRC cells and increased cell proliferation.

Indexed as

Cell ProliferationDNA MethylationResponse ElementsSignal TransductionCell Line, TumorColorectal NeoplasmsDNA, NeoplasmE2F1 Transcription FactorHumansMicroRNAsNeoplasm ProteinsRNA, NeoplasmStem Cell FactorDNA, NeoplasmE2F1 protein, humanE2F1 Transcription FactorMicroRNAsMIRN34 microRNA, humanNeoplasm ProteinsRNA, NeoplasmStem Cell Factorcolorectal cancerE2F1hyper-methylationmiR-34cp53stem cell factor (SCF)

Identifiers

PMID26704889
PMCPMC4741184
OpenAlexW2203066458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.